Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca and the UK's University of Manchester have entered into an agreement to enhance each organization's research into diseases such as cancer, inflammatory diseases, diabetes and obesity.
Subscribe to our email newsletter
The agreement sets out how the university and AstraZeneca will work together to identify new ways to treat disease and enhance discovery, preclinical and clinical research in a bid to better understand a variety of conditions. Under the agreement, the university and AstraZeneca will exchange staff, share facilities and encourage joint ventures through long-term funded collaborations.
The parties will also focus on enabling technologies such as imaging, informatics and chemistry that have the potential to identify and accelerate drug discovery in a number of different disease areas.
The agreement formalizes previous close contacts between the parties, such as the development of collaborative science networks.
“Teaming up with a company like AstraZeneca will increase our ability to attract the very best researchers, while providing AstraZeneca with access to new technologies, disease models and a large patient research base,” said Professor Alan North, University of Manchester vice president and dean of the faculty of life sciences.